Business, energy, technology, markets and global industry news from Business News Today

Royalty Pharma

PharmaDeviceNews Royalty Pharma
Pharma & Biotech

Teva TEV-408 protects against gluten-induced intestinal damage in Phase 2a celiac trial

Teva’s TEV-408 met the primary endpoint in a 50-patient Phase 2a celiac disease trial, significantly reducing gluten-induced intestinal damage while also limiting inflammatory-cell increases and gastrointestinal symptoms.

Read More
Neurimmune’s cliramitug royalty sale to Royalty Pharma for up to $425 million supports funding for its research pipeline as the ATTR-CM antibody advances through Phase 3 development. Representative image.
Pharma & Biotech

Why Royalty Pharma is betting up to $425m on Neurimmune’s Phase 3 heart drug

Neurimmune sells part of its cliramitug royalty to Royalty Pharma for up to $425 million as the ATTR-CM antibody advances through Phase 3.

Read More